

# Oracle Life Sciences CancerMPact

## Treatment Architecture Trends

Explore historical treatment trends to guide your commercialization strategy

### **Better understand global treatment trends**

Understanding historical global treatment patterns is essential for discerning the impact of market events on share and uptake of drugs and drug classes.

Explore a rich data set of annual drug treatment (by stage, patient segment and line of therapy), duration of therapy, modality, and outcomes data including:

- Data from 2017-current across 32 tumors
- 4 global geographies (US, EU5, JP, CN)

#### **Drug data can be queried and filtered by:**

- Technology (e.g. chemo, TKI, mAb, CAR-T autologous)
- Target (e.g. BTK, PD1, CD20)
- Drug/regimen

### **Unlock insights through an interactive user interface**

Utilize a web-based interface for customized data exploration, powerful analytics, and impactful visualization.

#### **Further analyze by:**

- Physician specialty (e.g. medical oncologist, hematologist, urologist, gynecologist)
- Treatment setting (e.g. academic medical center, community hospital, private practice)
- Individual EU5 country (DE, ES, FR, IT, UK)

# Historical data exploration made easier

## Better understand global treatment trends



Our oncology specialists have standardized historical data to allow for appropriate year-over-year comparisons and analyses.

## Data contextualized with drug approval dates

Drug approvals are annotated across geographies to provide contextual understanding of market trends.

## User support from oncology experts

Users have direct access to our Oracle Life Sciences CancerMPact team for further support in exploring these rich longitudinal datasets.



# Improving business outcomes through empowered decision making

Oracle Life Sciences CancerMPact is an invaluable and comprehensive oncology decision support resource. It can be utilized for market analysis, strategic planning and identification of commercial opportunities in the US, Western Europe, Japan and China. This resource is composed of cloud-based integrated modules: Patient Metrics (Patient Metrics – Core, Patient Metrics – Expanded Markets, PM Dashboards, and Biomarker Analysis), Treatment Architecture, Treatment Architecture Trends, and CancerLandscape.

## 1. Patient Metrics

Best-in-class cancer epidemiology and proprietary patient calculations for target markets.

**Patient Metrics Core** – US, Western Europe, Japan, China – combines epidemiologic data and analysis to estimate incidence (annual new cases of cancer) by stage; restaged 5-, 10-, or 15-year prevalence (annual surviving cancer patients from up to 15 years prior that accounts for progression to later stages); active disease (estimate of treatment-eligible patients by stage that does not include early-stage patients in remission); and treated patient populations by modality (surgery, radiation, drug therapy, etc.), drug regimens and drug agents.

**Patient Metrics Expanded Markets** – Combines epidemiologic data and analysis to estimate incidence (annual new cases of cancer) by stage; five-year prevalence (annual surviving cancer patients from up to five years prior; and treatable patients for up to 16 tumor types. Available for Argentina, Brazil, Canada, India, Mexico, Russia, South Korea, Taiwan and Turkey.

**PM Dashboards** – Interactive, multi-country views of the epidemiology and treatment of cancer, making comparisons across geographies, patients and tumors much easier. PM Dashboards features six interactive dashboards to allow you to more quickly and easily evaluate global trends in cancer epidemiology.

**Biomarker Analysis** – Expert analysis of key oncology biomarker segments. Biomarker Analysis is a global resource based on a thorough review of literature and recently published data that discusses the current and evolving oncology landscape with regard to biomarker segmentation rates and geographic, survival, ethnic, racial and gender differences.

## 2. Treatment Architecture

**In-depth quantitative analysis of oncology drug and modality utilization across all cancer disease stages.**

Treatment Architecture assesses the current clinical management of cancer patients by site and stage for all treatment modalities – including surgical, radiologic and systemic agents, as well as untreated patient populations. Treatment Architecture also provides pivotal clinical trial summaries to highlight the benchmark outcomes contributing to standard-of-care designations. Drug utilization is captured for all treatment settings and lines of therapy and by patient type in tumors where biomarkers have segmented the drug market.

## 3. Treatment Architecture Trends

**Analytics for in-depth exploration of historical treatment patterns.**

Treatment Architecture (TA) Trends allows for customized data exploration, powerful analytics, and impactful visualization of a wide variety of treatment data. TA Trends provides historical global treatment patterns allowing for analysis of the impact of market events on share and uptake of drugs and drug classes. A broad set of diagnostics, modality, drug, and outcomes data can be queried and filtered by stage, patient segment, drug technology, target, regimen, physician specialty, physician treatment setting and country.

## 4. Future Trends and Insights

**Expert analysis of the changing oncology competitive landscape with focus on ongoing pivotal clinical trials.**

Future Trends and Insights explores potential changes in treatment practices in the US, Western Europe and Japan based on a critical evaluation of recently published clinical data, regulatory advances/each tumor market, which can comprise new product introductions or label expansions of marketed products. It also assesses unmet needs for each cancer while continuously monitoring the competitive environment.

## 5. CancerLandscape

**A visual, competitive overview of the oncology drug and trial landscape**

CancerLandscape combines and standardizes US, EU, and Japan trial registries with other data sources to provide a visual and detailed understanding of the oncology trial landscape by company, tumor, drug and target. Users have the ability to filter on detailed clinical and commercial variables, make quick comparisons, uncover trends, and evaluate trial timing and enrollment. Gain insights about the oncology landscape in detail with a simple interface that is updated on a weekly basis. Clinical and scientific support is provided by the Oracle Life Sciences oncology support team.

Connect with us

Call **+1.800.ORACLE1** or visit **oracle.com**. Outside North America, find your local office at: **oracle.com/contact**.

 [blogs.oracle.com](https://blogs.oracle.com)

 [facebook.com/oracle](https://facebook.com/oracle)

 [twitter.com/oracle](https://twitter.com/oracle)

Copyright © 2025, Oracle and/or its affiliates. This document is provided for information purposes only, and the contents hereof are subject to change without notice. This document is not warranted to be error-free, nor subject to any other warranties or conditions, whether expressed orally or implied in law, including implied warranties and conditions of merchantability or fitness for a particular purpose. We specifically disclaim any liability with respect to this document, and no contractual obligations are formed either directly or indirectly by this document. This document may not be reproduced or transmitted in any form or by any means, electronic or mechanical, for any purpose, without our prior written permission.

Oracle, Java, MySQL, and NetSuite are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Some regulatory certifications or registrations to products or services referenced on this website are held by Cerner Corporation. Cerner Corporation is a wholly-owned subsidiary of Oracle. Cerner Corporation is an ONC-certified health IT developer and a registered medical device manufacturer in the United States and other jurisdictions worldwide.

This document may include some forward-looking content for illustrative purposes only. Some products and features discussed are indicative of the products and features of a prospective future launch in the United States only or elsewhere. Not all products and features discussed are currently offered for sale in the United States or elsewhere. Products and features of the actual offering may differ from those discussed in this document and may vary from country to country. Any timelines contained in this document are indicative only. Timelines and product features may depend on regulatory approvals or certification for individual products or features in the applicable country or region.